Cancer Cellular Therapy
Adaptive has partnered with Genentech, a member of the Roche Group, to develop, manufacture, and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. We aim to build a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer.
Adaptive has partnered with Microsoft to map and decode the human immune system, nature’s most finely tuned diagnostic. The ultimate goal is to potentially develop a diagnostic product that may enable early detection of multiple diseases from a single blood test.
Adaptive works with over 125 biopharmaceutical partners in over 150 trials per year across the research and development value chain to incorporate proven immune-driven metrics and screening capabilities into translational analyses, diagnostic tools and drug discovery efforts. We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkers of efficacy or adverse events for later stage trials, and screen for drug candidates that utilize or leverage the acumen of the immune system. In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers, and novel target screening.
Adaptive works with academic investigators, government-sponsored scientific institutions, and cooperative research organizations globally to incorporate immune profiling into high-impact research and clinical trials across disease settings. We work closely with teams on study design, sequencing, data analysis, and publication, with the overall goal of using immune repertoire dynamics to understand disease and host interactions, stratify patient populations, determine potential biomarkers of drug response, and ultimately improve patient outcomes.